{
 "generic_name": "Insulin Glargine-aglr Injection",
 "slug": "insulin-glargine-aglr-injection",
 "brand_names": [
  "Rezvoglar Kwikpen"
 ],
 "fda_status": [
  "To Be Discontinued"
 ],
 "last_fda_update": "09/01/2026",
 "first_posted": "09/01/2026",
 "synced_at": "2026-10-01T04:04:04.751Z",
 "presentations": [
  {
   "company": "Eli Lilly and Co.",
   "package_ndc": "0002-8980-05",
   "presentation": "Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)",
   "availability": "Not specified",
   "availability_raw": null,
   "fda_note": "A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance."
  }
 ],
 "changes": []
}